Current Edition

cost

Taking a Long-Term Approach to Improving Vaccine Trial Recruitment

The groundbreaking mRNA technology used in the COVID-19 vaccine has potential applications in preventing a number of other infectious diseases and is ushering in a …

Continue Reading →
BioNTech

BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report

Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come. Germany will pay …

Continue Reading →
biologics

Samsung Biologics outlines mRNA ambitions as “Super Plant” speeds toward completion

Samsung Biologics has been on an expansion sprint, with plans to speedily complete a so-called Super Plant already giving way to designs on follow-up facilities …

Continue Reading →
manufacturing

Ginkgo and Aldevron tout mRNA manufacturing ‘breakthrough’—and the perks could stretch well beyond COVID-19, exec says

A multibillion-dollar SPAC deal? Check. An international acquisition? Check. An mRNA vaccine production “breakthrough?” Ginkgo Bioworks says it has that, too. With its latest manufacturing …

Continue Reading →
BioNTech

BioNTech, eyeing $18B-plus in COVID-19 vaccine sales this year, poised to join the ranks of the world’s top drugmakers

The COVID-19 pandemic helped put mRNA vaccines on the map. Now, thanks to the shots’ quick uptake in rich countries, mRNA specialist BioNTech appears poised …

Continue Reading →